Houlihan Lokey is pleased to announce the sale of Cyalume Technologies Holdings, Inc., (Cyalume) to Arsenal Capital Partners (Arsenal). The transaction closed on September 8, 2017.
Cyalume designs and manufactures specialty chemicals for use in pharmaceutical, medical, commercial, and military markets. The company sells to major pharmaceutical and medical device companies throughout the world, the domestic military, and international militaries. Cyalume is headquartered in Ft. Lauderdale, Florida, and has manufacturing locations in West Springfield, Massachusetts, and Bound Brook, New Jersey, as well as a subsidiary, Cyalume Technologies, SAS, located in Aix-en-Provence, France.
Arsenal is a leading New York-based private equity firm that specializes in investments in middle-market specialty industrials and healthcare companies. Since inception, Arsenal has raised institutional equity investment funds of approximately $3 billion. The firm works with management teams to build strategically important companies with leading market positions, high growth, and high value-add.